CN104524180A - Maca compound tablet, and preparation method and applications thereof - Google Patents

Maca compound tablet, and preparation method and applications thereof Download PDF

Info

Publication number
CN104524180A
CN104524180A CN201410673994.3A CN201410673994A CN104524180A CN 104524180 A CN104524180 A CN 104524180A CN 201410673994 A CN201410673994 A CN 201410673994A CN 104524180 A CN104524180 A CN 104524180A
Authority
CN
China
Prior art keywords
parts
maca
meyenii walp
lepidinm meyenii
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410673994.3A
Other languages
Chinese (zh)
Inventor
纪超群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FUJIAN KEAO BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CENTER Co Ltd
Original Assignee
FUJIAN KEAO BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CENTER Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FUJIAN KEAO BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CENTER Co Ltd filed Critical FUJIAN KEAO BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CENTER Co Ltd
Priority to CN201410673994.3A priority Critical patent/CN104524180A/en
Publication of CN104524180A publication Critical patent/CN104524180A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/31Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/35Caprifoliaceae (Honeysuckle family)
    • A61K36/355Lonicera (honeysuckle)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • A61K36/804Rehmannia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969Polygonatum (Solomon's seal)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a maca compound tablet, and a preparation method and applications thereof. The maca compound tablet is composed of 25 to 60 parts of maca, 5 to 20 parts of fructus tribuli, 1 to 10 part of rhizoma polygonati, 3 to 20 parts of prepared rehmannia root, 1 to 15 parts of American ginseng, 1 to 10 parts of strigose hydrangea juvenile leaf, 1 to 15 parts of lonicera japonica, and 30 to 40 parts of an auxiliary material. The maca compound tablet is capable of avoiding imbalance of yin and yang, damage of vitality, and injure of the five internal organs which are caused by overemphasis on yang tonifying effects of maca products, and solving problems of maca products that taste is poor and piquancy, and internal heat is easily caused. The maca compound tablet is capable of relieving fatigue and improving immunity, and possesses excellent treatment effects.

Description

A kind of Maca composite sheet and preparation method thereof and application
Technical field
The invention belongs to technical field of traditional Chinese medicine preparation, relate to a kind of Maca composite sheet, is a kind of Maca composite sheet and preparation method thereof and application in particular.
Background technology
Lepidinm meyenii Walp (Maca, Peruvian ginseng), Cruciferae (Cruciferae) Lepidium (Lepidium) plant, have the laudatory title of " Peru's Radix Ginseng ", is called " natural hormone electromotor " by international medicinal plants circle.Contained abundant and unique nutritional labeling, chemical composition and bioactive substance, as the aminoacid, alkaloid (Lepidinm meyenii Walp alkene, macamide) etc. of sterol, sinigrin oil, unsaturated fatty acid, nutrient and needed by human, for human physical and mental health, treatment illness, life lengthening, to produce offspring and life power provides the approach of the space of research, the prospect of exploitation and clear one's mind of doubt, for life sciences, health care and bio-pharmaceuticals provide new natural plant raw material material base.
Lepidinm meyenii Walp has had more than 5800 year in the edible history in South America, traditionally for strengthening body, improves fertility, improvement function, antidepressant, anti-anemia action etc.Phase early 1960s is to the eighties, about the research progressively systematization of Lepidinm meyenii Walp botany and medical value, some traditional role of Lepidinm meyenii Walp obtain the scientific validation of Germany and North American Plant researcher, especially after the eighties, FAO (Food and Agriculture Organization of the United Nation) (FAO) advises that the plantation to Lepidinm meyenii Walp is promoted in countries in the world, the chemical composition of Lepidinm meyenii Walp is identified, active component is separated and pharmacological action etc. obtains further discussion, and wherein Lepidinm meyenii Walp improves fertility, improvement function, anticancer, leukemia, treatment climacteric syndrome etc. act on becomes current study hotspot.At the beginning of the nineties, researcher has found that when finding " viagra " succedaneum Lepidinm meyenii Walp is improving the remarkable efficacy on sexual function, makes Lepidinm meyenii Walp become a nova in international health product and medicine at one stroke.For over ten years, through the research and practice of countries in the world scientific researcher to Lepidinm meyenii Walp pharmacological effect, health-care effect, Mechanism of characters and clinical experiment, confirm that Lepidinm meyenii Walp is improved the quality of living to body-care, to multiple difficult illness treatment, to continuity life slow down aging etc., there is significant effect.Thus be subject to global extensive accreditation, food and agricultural organization of united state is classified as rare supplementary, is classified as rare plant (1992) by International Plant Genetic Resources Institute; For world mountain-climbing confederation (UIAA) appointed product (2000); For American Space General Administration (NASA) specifies space grain (calendar year 2001); Listed in health food (calendar year 2001) by U.S. FDA, be classified as new resource food (2011) by China, for Korean and Japanese world cup athlete specifies nutriment.
Current existing disclosed Maca tablet, mainly contain CN201210333499, it is by pueraria root powder 581.84, microcrystalline Cellulose, lactose, polyvidone, magnesium stearate, starch form, be mainly used for alleviating physical fatigue, improvement function, improve fertility, endocrine regulation etc.
Another one application CN103652092A discloses Maca tea oral tablet and preparation method thereof, and it is made up of Lepidinm meyenii Walp, instant tea powder, microcrystalline Cellulose, Sorbitol, other adjuvants, magnesium stearate and natural perfume material etc.There is resisting fatigue, regain one's strength, improve the effects such as memory.Have a confection Maca tablet CN201410058092 again, it forms by containing stachyose Lepidinm meyenii Walp pressed candy and Maca tablet, complete, the easy to digest absorption of product Lepidinm meyenii Walp nutrition, enhancing reproductive system function; Can regulating intestinal canal microecological balance, reduce cholesterol, improve immunity, do not rely on insulin metabolism, promote the trace elements absorption such as Ca, Mg, delay hypomnesis, anti-caries.
There is CN201410056716 to provide one again and do not add any adjuvant, the pure Maca tablet of part and Lepidinm meyenii Walp Extraction parts common combination is only pulverized by Lepidinm meyenii Walp, mainly solve pueraria root powder and be used alone the problem being difficult to tabletting, solve again the independent dry very difficult problem of Maca extract.
The above-mentioned disclosed Compound Tablet compatibility defectiveness containing Lepidinm meyenii Walp overemphasizes YANG invigorating, and causes imbalance of YIN and YANG, essence of being impairment of the kidney, vigour of hindering, damages the five internal organs etc.; Bioavailability is low, and mouthfeel is not good, pungent, and the probability of generation oral ulcer of easily getting angry is very high.Compound preparation about Lepidinm meyenii Walp composition has no report in assisting in treating hypertension, hyperlipidemia.
Summary of the invention
This patent is intended to solve the overemphasized YANG invigorating effect of Lepidinm meyenii Walp series products and the imbalance of YIN and YANG that may cause, essence of being impairment of the kidney, vigour of hindering, damage the defects such as the five internal organs, and solves the defect that Lepidinm meyenii Walp products taste is not good, pungent, easily get angry.According to the traditional Chinese medical science " monarch " compatibility principle, allocate that a kind of bioavailability is high, mouthfeel is good, not easily get angry, the Maca composite sheet of assisting in treating hypertension that negative and positive are coordinated, hyperlipidemia.
The invention discloses following technology contents for achieving the above object:
A kind of Maca composite sheet, is characterized in that it is made up of the raw material of following portions by weight:
Lepidinm meyenii Walp 25 ~ 60 parts, disease Herba chenopodii 5 ~ 20 parts, Rhizoma Polygonati 1 ~ 10 part, Radix Rehmanniae Preparata 3 ~ 20 parts,
Radix Panacis Quinquefolii 1 ~ 15 part, Folium hydrangeae strigosae 1 ~ 10 part, Flos Lonicerae 1 ~ 15 part, adjuvant 30 ~ 40 parts.
The preferred Maca composite sheet of the present invention, is characterized in that it is made up of the raw material of following portions by weight:
Lepidinm meyenii Walp 42-50 part, disease Herba chenopodii 7-15 part, Rhizoma Polygonati 3-5 part, Radix Rehmanniae Preparata 7-10 part, Radix Panacis Quinquefolii 5-10 part,
Folium hydrangeae strigosae 2-5 part, Flos Lonicerae 4-10 part, adjuvant 30-25 part.
The Maca composite sheet that the present invention is more preferably, is characterized in that it is made up of the raw material of following portions by weight:
Lepidinm meyenii Walp 42 parts, disease Herba chenopodii 7 parts, Rhizoma Polygonati 3 parts, Radix Rehmanniae Preparata 7 parts, Radix Panacis Quinquefolii 5 parts, Folium hydrangeae strigosae 2 parts, Flos Lonicerae 4 parts, adjuvant 30 parts.
The present invention further discloses the preparation method of Maca composite sheet, it is characterized in that being undertaken by following step:
(1) the Lepidinm meyenii Walp fresh fruit that kind is pure, activity substance content is high is chosen, through section, oven dry, pulverizing, 300 order sieving for standby; Choose the oven dry of disease Herba chenopodii, pulverizing, 300 order sieving for standby; Get Rhizoma Polygonati and add that yellow wine water proof steams, dries, pulverizes, 300 order sieving for standby; Radix Rehmanniae (get bosom celebrating area), through steaming, drying, pulverize, 300 order sieving for standby, gets Radix Panacis Quinquefolii, Folium hydrangeae strigosae, Flos Lonicerae, pulverizes respectively, to cross 300 mesh sieves for subsequent use;
(2) above-mentioned ground product is mixed in proportion, and adds the adjuvant such as pregelatinized Starch, microcrystalline Cellulose, tabletted; Described each raw material:
Lepidinm meyenii Walp 25 ~ 60 parts, disease Herba chenopodii 5 ~ 20 parts, Rhizoma Polygonati 1 ~ 10 part, Radix Rehmanniae Preparata 3 ~ 20 parts,
Radix Panacis Quinquefolii 1 ~ 15 part, Folium hydrangeae strigosae 1 ~ 10 part, Flos Lonicerae 1 ~ 15 part, adjuvant 30 ~ 40 parts.
The present invention adds Guangxi production-sweet tea in the process of preparation, and production-sweet tea is fragrant and sweet strong, not bitter oiliness, bubbles out chlorophyll and enriches, be of high nutritive value.
The present invention further discloses Maca composite sheet in preparation fatigue alleviating, the application of enhancing immunity aspect.Application particularly in preparation auxiliary treatment hyperlipidemia, hypertension.Instructions of taking: oral, 2 times/day, 1 ~ 2 piece/times, (medicine) being taken before meal is used sooner or later.
The too outstanding Lepidinm meyenii Walp YANG invigorating effect difference of Maca composite sheet disclosed by the invention and existing scheme is:
(1) the present invention is monarch drug according to traditional Chinese medical science combination principle with Lepidinm meyenii Walp, has balance hormone, strengthens body immunity, endocrine regulation, recovery physiological function, improvement function, improves fertility, blood fat reducing, blood pressure lowering, balance blood sugar, neuroprotective cell, alleviates climacteric syndrome etc.; Disease Herba chenopodii suppressing the hyperactive liver resolving depression, invigorate blood circulation supporing yang; Rhizoma Polygonati nourishing YIN and moistening the lung, invigorating the spleen and replenishing QI; Radix Rehmanniae Preparata nourishing the blood and yin, vital essence replenishing and marrow benifiting, Radix Panacis Quinquefolii boosting qi and nourishing yin, clearing away heat and promoting production of body fluid, four can work in coordination with the balance that Lepidinm meyenii Walp regulates negative and positive, nature and flavor, QI and blood and health-care effect, are ministerial drug; Folium hydrangeae strigosae heat-clearing and toxic substances removing, moistening the lung and resolving phlegm, Flos Lonicerae heat-clearing and toxic substances removing, the two can be in harmonious proportion the warm nature of Lepidinm meyenii Walp, disease Herba chenopodii, Radix Rehmanniae Preparata, also can in and the acid of Lepidinm meyenii Walp, for assistant makes.
(2) the present invention can solve the overemphasized YANG invigorating effect of existing Lepidinm meyenii Walp series products and the disorder such as negative and positive, nature and flavor, QI and blood, effect that may cause, and the essence of being impairment of the kidney caused, vigour of hindering, damage the defect such as the five internal organs, and solve the defect that existing Lepidinm meyenii Walp series products mouthfeel is not good, pungent, easily get angry.
(3) Maca composite sheet of the present invention has the effect of blood pressure lowering, blood fat reducing, is more applicable to diabetic to take.
The project of Maca composite sheet finished product detection prepared by the present invention is as follows:
(1) organoleptic detection
Check by the regulation of operative norm, coating water white transparency, label is faint yellow, uniform color, and overall appearance is oblong, has suitable hardness, granulate free from extraneous odour, is as good as and smells, without going mouldy.
(2) water content detects
The assay method of moisture in GB/T 5009.3 food
(3) total ash measures
The mensuration of ash in GB 5009.4 food
(4) heavy metal analysis
The assay method of arsenic GB/T 5009.11 total Arsenic in Food detects limitation≤0.5mg/kg
The assay method of plumbous GB/T 5009.12 Pb in food detects limitation≤0.3mg/kg
(5) the residual detection of agriculture
Gamma Hexaochlorocyclohexane, detectability figureofmerit :≤0.2mg/kg
Clofenotane, detectability figureofmerit :≤0.2mg/kg
The assay method of Gamma Hexaochlorocyclohexane, clofenotane residual quantity in GB/T 5009.19-1996 food
(6) microorganism detection
GB 4789.2 microbiological test of food hygiene total plate count measures and detects limitation≤30000cfu/g
GB 4789.3 microbiological test of food hygiene coliform measures and detects limitation≤90MPN/100g
The inspection of GB 4789.4 microbiological test of food hygiene Salmonella is limited the quantity---
The inspection of GB 4789.5 microbiological test of food hygiene shigella is limited the quantity---
The inspection of GB 4789.10 microbiological test of food hygiene staphylococcus aureus is limited the quantity---
The inspection of GB 4789.11 microbiological test of food hygiene Hemolytic streptococcus is limited the quantity---
GB 4789.15 food hygiene Micro biological Tests Molds and yeasts count detection is limited the quantity ≤ 25 cfu/g
(7) disintegration
Check by the regulation of operative norm ,≤60min
(8) functional component/significant composition
Lepidinm meyenii Walp alkene >=0.2%
Check by the regulation of operative norm
In order to prove that Maca composite sheet disclosed by the invention is in fatigue alleviating, the application of enhancing immunity aspect.Actual effect particularly in auxiliary treatment hyperlipidemia, hypertension, the present invention adds single component Lepidinm meyenii Walp (the 5th group of aqueous solution) for the product that typical embodiment 1 is obtained simultaneously, has carried out following test:
One, resisting fatigue and immunity test: take Kunming mouse as experimental subject, provided by Shanghai Slac Experimental Animal Co., Ltd., selects the healthy mice 16 of 18 ~ 22g, and each 8 of male and female, are divided into four groups, often organizes two female two heros:
First group is blank group;
Second group is feed an embodiment 1(every day to be made into aqueous solution) 1 2ml, feeds 20 days continuously;
3rd group is feed twice embodiment 1(every day to be made into aqueous solution) 1 3ml, feeds 20 days continuously;
4th group is feed twice embodiment 1(every day to be made into aqueous solution) 1 6ml, feeds 20 days continuously;
5th group is feed twice embodiment 1(every day to be made into aqueous solution) 1 6ml, feeds 20 days continuously.
(1) anti-fatigue test
1) Loaned swimming test
Drop in the warm water of 25 DEG C by four groups of mices, Mus tail ties up the stone of same weight, the time that record mice is adhered to, result is as shown in table 1,
Table 1 bears a heavy burden result of the test
2) running test
Be placed in by five groups of mices and rotate mouse cage, record mice running time and rest number of times, the results are shown in Table shown in 2,
Table 2 is run and is tested
As can be seen from table 1 and table 2, the mice of 1-4 group, endurance and muscle power increase all gradually, and the 5th group of endurance is identical with the 4th group with muscle power.
(2) immunity test
To the influenza virus of five groups of injected in mice 0.1ml after test of running, observe the performance of four groups of mices, the results are shown in Table 3.
Table 3 immunity test
As can be seen from Table 3,1-4 group, the immunity of mice strengthens gradually.The immunity of the 5th group of mice is identical with the 3rd group.
Conclusion:
The effect that the mice of (1) 1-4 group demonstrates at test of bearing a heavy burden, test of running, immunity test strengthens gradually.
(2) the 5th groups of mices are in test of bearing a heavy burden, test of running, immunity test display: only demonstrate at Loaned swimming test the time that the mice than the 4th group adheres to longer, and the mice characteristic that test is identical with the mice characteristic of the 4th group, immunity is tried to demonstrate with the 3rd group of running is identical.
Two, auxiliary treatment hyperlipidemia, hypertension test:
Physical data: statistics 63 routine cases in 2012, wherein male 42 example, women 21 example, max age 72 years old, minimal ages 32 years old, 45.3 years old mean age.
Diagnostic criteria: diagnosed by B ultrasonic and be diagnosed as fatty liver, wherein severe fatty liver 12 example, moderate 24 Cases of Fatty Liver, mild fatty liver 33 example.
Lipid examination: T-CHOL, triglyceride.Wherein 61 routine patient main suits have weak, off feed in various degree, feel sick, the symptom such as abdominal distention, uncomfortable liver area.
Therapeutic Method: " the Maca composite sheet " that adopt this prescription to make, every day 2 times, on an empty stomach morning and evening service once.Treatment suitably adds sharp movement simultaneously, controls high sugar, high fat diet, wine for giving off smoking, within 3 months, is 1 course for the treatment of.
Clinical symptoms and sign are observed: to weak, off feed, feel sick, the symptom such as abdominal distention, uncomfortable liver area and the sign such as liver size and tenderness observe in detail, record 1 time weekly, before and after treatment, do liver B ultrasonic and lipid examination.
Curative effect determinate standard: formulate criterion of therapeutical effect with reference to Ministry of Public Health " new Chinese medicine guideline of clinical investigations ",
Effective: ultrasonic display fatty liver disappears, rate and blood-lipid decreased is to normal range, and liver function is normal, and subjective symptoms disappears; Effective: ultrasonic examination fatty liver degree alleviates, rate and blood-lipid decreased > 10%, subjective symptoms takes a turn for the better;
Invalid; Symptom is without change, and ultrasonic examination fatty liver degree is unchanged, rate and blood-lipid decreased < 10%.
Therapeutic outcome: after treating March, effective 41 examples, effective 8 examples, invalid 14 examples, total effective rate 77.78 %.
Model case 1:
Lee, man, 56 years old, certain real estate group afforestation project director.Because having a lot of work to do, feel very tired, every night wants once going back rest of lying down.Addicted to tobacco and wine, eating meat, fatty liver is found in health check-up the year before, and hyperlipemia does not give attention.
Physical examination: pulsation 73 beats/min, BP135/90mmHg, ordinary circumstance is good, god is clear, chronic facies, and complexion is impractical, abdomen is soft, and full abdomen is without tenderness, and liver can touch in sword that next refers to, matter is soft, smooth surface, without tenderness, remaining without special signs, patient is previously without infection medical histories such as " hepatitis ", and pale tongue dark tongue the lung-pulse is fine and smooth.
Laboratory examination: liver function is normal, T-CHOL 7.5mmol/L, (< 5.7mmol/L), triglyceride 5.0mmol/L (< 1.71mmol/L); B ultrasonic shows: moderate fatty liver.
Western medicine diagnose: 1. hyperlipemia 2. fatty liver: tcm diagnosis the liver rump stagnation of liver-QI with deficiency of the spleen.Adopt " Maca composite sheet ", every day 2 times, sooner or later service once, each 2.And advise patient to avoid tobacco and wine, low fat diet.Take medicine after 20d, subjective symptoms is clearly better, and serve on 2 months, check blood fat T-CHOL 5.3mmol/L, (< 5.7mmol/L), triglyceride 2.7mmol/L (< 1.71mmol/L) is normal, B ultrasonic liver and gall no abnormality seen.
Model case 2:
Chen, 49 years old, certain proprietor of an establishment, because portfolio is large, pressure was large, frequent continuous operation and normally not having a rest, and body abnormality is tired out, is all difficult to the work of concentrating one's energy every day, and working effect is poor.Found slight Hypertension 160/120mmHg during unit health check-up before half a year, recently feel uneasy, inspection of going to see a doctor, still exceeds normal range.Be diagnosed as essential hypertension, pressure value is 180/120mmHg, lipid examination: cholesterol 9.11 mmol/L, and the cholesterol in the highest 4.9 mmol/L serum of triglyceride and triglyceride obviously raise, and brain magnetic resonance imaging shows slight cerebral infarction.Tentatively be diagnosed as hypertension, hyperlipidemia, slight cerebral infarction.
Adopt " Maca composite sheet ", every day 2 times, sooner or later service once, each 2.And advise patient to avoid tobacco and wine, low-fat low-salt diet.Take medicine after 20d, blood pressure 150/110mmHg, the symptom of dizziness and blurred vision, numb limbs and tense tendons all makes moderate progress, and subjective symptoms is clearly better, and serve on January, blood fat check T-CHOL 7.3mmol/L, triglyceride 3.9mmol/L.Serve on 3 months pressure 140/100mmHg, blood fat check T-CHOL 5.5mmol/L, triglyceride 2.9mmol/L.
This patent emphasizes the traditional Chinese medical science " monarch " compatibility principle, emphasize the coordination of negative and positive, nature and flavor, QI and blood and effect, there is resisting fatigue, effect of auxiliary antilipemic, blood pressure lowering. be monarch drug with Lepidinm meyenii Walp, there is balance hormone, strengthen body immunity, endocrine regulation, recovery physiological function, improvement function, improve fertility, blood fat reducing, blood pressure lowering, balance blood sugar, neuroprotective cell, alleviate climacteric syndrome etc.; Disease Herba chenopodii suppressing the hyperactive liver resolving depression, invigorate blood circulation supporing yang; Rhizoma Polygonati nourishing YIN and moistening the lung, invigorating the spleen and replenishing QI; Radix Rehmanniae Preparata nourishing the blood and yin, vital essence replenishing and marrow benifiting, Radix Panacis Quinquefolii boosting qi and nourishing yin, clearing away heat and promoting production of body fluid, four can work in coordination with the balance that Lepidinm meyenii Walp regulates negative and positive, nature and flavor, QI and blood and health-care effect, are ministerial drug; Folium hydrangeae strigosae heat-clearing and toxic substances removing, moistening the lung and resolving phlegm, Flos Lonicerae heat-clearing and toxic substances removing, the two can be in harmonious proportion the warm nature of Lepidinm meyenii Walp, disease Herba chenopodii, Radix Rehmanniae Preparata, also can in and the acid of Lepidinm meyenii Walp, for assistant makes.
And like product formula is only consider to improve drinking person fatigue symptom and simple compatibility, do not consider its coordinative role.In addition, the simplification considered portability Yu take, the present invention adopts Tabules.
Detailed description of the invention
In order to simple and clearly object, the hereafter appropriate description eliminating known technology, in order to avoid the unnecessary description of details impact to the technical program.Below in conjunction with comparative example, the present invention is described further.Wherein used Chinese crude drug all has commercially available.It should be noted that Radix Rehmanniae is the Radix Rehmanniae of bosom celebrating.
Embodiment 1(w/w)
(1) the Lepidinm meyenii Walp fresh fruit that kind is pure, activity substance content is high is chosen, through section, oven dry, pulverizing, 300 order sieving for standby; Choose the oven dry of disease Herba chenopodii, pulverizing, 300 order sieving for standby; Get Rhizoma Polygonati and add that yellow wine water proof steams, dries, pulverizes, 300 order sieving for standby; Get bosom to celebrate one's birthday Radix Rehmanniae, through steaming, drying, pulverize, 300 order sieving for standby, get Radix Panacis Quinquefolii, Folium hydrangeae strigosae, Flos Lonicerae, pulverize respectively, to cross 300 mesh sieves for subsequent use;
(2) above-mentioned ground product is mixed in proportion, and adds the adjuvant such as pregelatinized Starch, microcrystalline Cellulose, tabletted; Described each raw material: Lepidinm meyenii Walp 42%, disease Herba chenopodii 7%, Rhizoma Polygonati 3%, Radix Rehmanniae Preparata 7%, Radix Panacis Quinquefolii 5%, Folium hydrangeae strigosae 2%, Flos Lonicerae 4%, adjuvant 30%.Instructions of taking: oral, 2 times/day, 2 pieces/times, (medicine) being taken before meal is used sooner or later.
Embodiment 2
(1) the Lepidinm meyenii Walp fresh fruit that kind is pure, activity substance content is high is chosen, through section, oven dry, pulverizing, 300 order sieving for standby; Choose the oven dry of disease Herba chenopodii, pulverizing, 300 order sieving for standby; Get Rhizoma Polygonati and add that yellow wine water proof steams, dries, pulverizes, 300 order sieving for standby; Get bosom to celebrate one's birthday Radix Rehmanniae, through steaming, drying, pulverize, 300 order sieving for standby, get Radix Panacis Quinquefolii, Folium hydrangeae strigosae, Flos Lonicerae, pulverize respectively, to cross 300 mesh sieves for subsequent use;
(2) above-mentioned ground product is mixed in proportion, and adds the adjuvant such as pregelatinized Starch, microcrystalline Cellulose, tabletted; Described each raw material: Lepidinm meyenii Walp 25 parts, disease Herba chenopodii 20 parts, Rhizoma Polygonati 10 parts, Radix Rehmanniae Preparata 3 parts, Radix Panacis Quinquefolii 15 parts, Folium hydrangeae strigosae 1 part, Flos Lonicerae 15 parts, adjuvant 40 parts.Instructions of taking: oral, 2 times/day, 2 pieces/times, (medicine) being taken before meal is used sooner or later.
Embodiment 3
(1) the Lepidinm meyenii Walp fresh fruit that kind is pure, activity substance content is high is chosen, through section, oven dry, pulverizing, 300 order sieving for standby; Choose the oven dry of disease Herba chenopodii, pulverizing, 300 order sieving for standby; Get Rhizoma Polygonati and add that yellow wine water proof steams, dries, pulverizes, 300 order sieving for standby; Get bosom to celebrate one's birthday Radix Rehmanniae, through steaming, drying, pulverize, 300 order sieving for standby, get Radix Panacis Quinquefolii, Folium hydrangeae strigosae, Flos Lonicerae, pulverize respectively, to cross 300 mesh sieves for subsequent use;
(2) above-mentioned ground product is mixed in proportion, and adds the adjuvant such as pregelatinized Starch, microcrystalline Cellulose, tabletted; Described each raw material: Lepidinm meyenii Walp 60 parts, disease Herba chenopodii 5 parts, Rhizoma Polygonati 8 parts, Radix Rehmanniae Preparata 10 parts, Radix Panacis Quinquefolii 15 parts, Folium hydrangeae strigosae 8 parts, Flos Lonicerae 15 parts, adjuvant 35 parts.Instructions of taking: oral, 2 times/day, 2 pieces/times, (medicine) being taken before meal is used sooner or later.

Claims (6)

1. a Maca composite sheet, is characterized in that it is made up of the raw material of following portions by weight:
Lepidinm meyenii Walp 25 ~ 60 parts, disease Herba chenopodii 5 ~ 20 parts, Rhizoma Polygonati 1 ~ 10 part, Radix Rehmanniae Preparata 3 ~ 20 parts,
Radix Panacis Quinquefolii 1 ~ 15 part, Folium hydrangeae strigosae 1 ~ 10 part, Flos Lonicerae 1 ~ 15 part, adjuvant 30 ~ 40 parts.
2. Maca composite sheet described in claim 1, is characterized in that it is made up of the raw material of following portions by weight:
Lepidinm meyenii Walp 42-50 part, disease Herba chenopodii 7-15 part, Rhizoma Polygonati 3-5 part, Radix Rehmanniae Preparata 7-10 part, Radix Panacis Quinquefolii 5-10 part,
Folium hydrangeae strigosae 2-5 part, Flos Lonicerae 4-10 part, adjuvant 30-25 part.
3. Maca composite sheet described in claim 1, is characterized in that it is made up of the raw material of following portions by weight:
Lepidinm meyenii Walp 42 parts, disease Herba chenopodii 7 parts, Rhizoma Polygonati 3 parts, Radix Rehmanniae Preparata 7 parts, Radix Panacis Quinquefolii 5 parts,
Folium hydrangeae strigosae 2 parts, Flos Lonicerae 4 parts, adjuvant 30 parts.
4.(1) choose the Lepidinm meyenii Walp fresh fruit that kind is pure, activity substance content is high, through section, oven dry, pulverizing, 300 order sieving for standby; Choose the oven dry of disease Herba chenopodii, pulverizing, 300 order sieving for standby; Get Rhizoma Polygonati and add that yellow wine water proof steams, dries, pulverizes, 300 order sieving for standby; Radix Rehmanniae, through steaming, drying, pulverize, 300 order sieving for standby, gets Radix Panacis Quinquefolii, Folium hydrangeae strigosae, Flos Lonicerae, pulverizes respectively, to cross 300 mesh sieves for subsequent use;
(2) above-mentioned ground product is mixed in proportion, and adds the adjuvant such as pregelatinized Starch, microcrystalline Cellulose, tabletted; Described each raw material:
Lepidinm meyenii Walp 25 ~ 60 parts, disease Herba chenopodii 5 ~ 20 parts, Rhizoma Polygonati 1 ~ 10 part, Radix Rehmanniae Preparata 3 ~ 20 parts,
Radix Panacis Quinquefolii 1 ~ 15 part, Folium hydrangeae strigosae 1 ~ 10 part, Flos Lonicerae 1 ~ 15 part, adjuvant 30 ~ 40 parts.
5. Maca composite sheet described in any one of claim 1-2 is in preparation fatigue alleviating, the application of enhancing immunity aspect.
6. the application of Maca composite sheet described in any one of claim 1-2 in preparation auxiliary treatment hyperlipidemia, hypertension.
CN201410673994.3A 2014-11-24 2014-11-24 Maca compound tablet, and preparation method and applications thereof Pending CN104524180A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410673994.3A CN104524180A (en) 2014-11-24 2014-11-24 Maca compound tablet, and preparation method and applications thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410673994.3A CN104524180A (en) 2014-11-24 2014-11-24 Maca compound tablet, and preparation method and applications thereof

Publications (1)

Publication Number Publication Date
CN104524180A true CN104524180A (en) 2015-04-22

Family

ID=52839936

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410673994.3A Pending CN104524180A (en) 2014-11-24 2014-11-24 Maca compound tablet, and preparation method and applications thereof

Country Status (1)

Country Link
CN (1) CN104524180A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104920762A (en) * 2015-06-30 2015-09-23 福建德广中草药有限公司 Huangjing Maka tablet sugar and production method thereof
CN105641417A (en) * 2016-02-04 2016-06-08 湖南宁和保健品有限公司 Solid health care medicine capable of improving essence, qi and spirit and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103584098A (en) * 2013-11-16 2014-02-19 丽江玛咖生物科技有限公司 Maca almond tablet and preparation method thereof
CN104095231A (en) * 2014-06-20 2014-10-15 云南省药物研究所 Health-care product containing mair conditioning unita, dendrobium and American ginseng and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103584098A (en) * 2013-11-16 2014-02-19 丽江玛咖生物科技有限公司 Maca almond tablet and preparation method thereof
CN104095231A (en) * 2014-06-20 2014-10-15 云南省药物研究所 Health-care product containing mair conditioning unita, dendrobium and American ginseng and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
李琼仙等: "玛卡的保健功能及其在会泽县的栽植现状", 《现代农业科技》 *
杨少华等: "云南玛咖产业发展现状及促进对策分析", 《世界科学技术-中医药现代化》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104920762A (en) * 2015-06-30 2015-09-23 福建德广中草药有限公司 Huangjing Maka tablet sugar and production method thereof
CN105641417A (en) * 2016-02-04 2016-06-08 湖南宁和保健品有限公司 Solid health care medicine capable of improving essence, qi and spirit and preparation method thereof

Similar Documents

Publication Publication Date Title
CN103445165B (en) A kind of for product improving sub-health state and combinations thereof thing
CN103463457B (en) Composite chewable tablet of Herba Dendrobii Hericium erinaceus (Bull. Ex Fr.) Pers. and preparation method thereof
CN106942748A (en) A kind of female acyesis tailored version clinical nutrition formula and preparation method thereof
CN103099089A (en) Health-care product for reducing blood sugar and blood pressure, relaxing bowels, losing weight, resisting fatigue and improving sexual function and production technology thereof
CN101579120A (en) Nutritional food with weight-losing function and preparation method thereof
CN102987477B (en) Health drink
CN101816425A (en) Powder mixture of whole American ginseng/giant salamander and preparation method thereof
CN105010669A (en) Refreshing and moistening health-care jasmine flower tea and production method thereof
CN102430038A (en) Composition for improving blood testosterone, and composition-containing preparation and preparation method thereof
CN106418501A (en) Healthcare food with weight reducing function
CN103445116B (en) Healthcare radix puerariae nutrition powder with blood fat regulating effect
CN109043553A (en) A kind of Special food and preparation method thereof that patients with gestational diabetes is edible
CN103238757B (en) Compound feed containing fermented cottonseed meal for chicken for eggs and preparation method thereof
KR20160000695A (en) Herbal-medicine containing dha for recovering fatigue and enhancing memory, and method of manufacturing the same
CN103920140B (en) A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation
CN104472787B (en) A kind of compound maca health protection tea and preparation method and application
CN104524180A (en) Maca compound tablet, and preparation method and applications thereof
CN1401758A (en) Process for preparing dietetic health vinegar, and dietetic heath vinegar produced thereby
CN105029420A (en) Maca moringa tablet
CN104397717A (en) Healthy anti-constipation corn weight-losing food and making method thereof
CN107233491A (en) It is a kind of to improve the antifatigue maca composition of energy
CN103798596B (en) Total nutrient formula food suitable for patients with cardiovascular and cerebrovascular diseases
CN103181557A (en) Nutritious food with slimming function and preparation method thereof
CN106562196A (en) Health-care food for patients suffering from chronic indigestion to eat, and preparation method of health-care food
CN103169125B (en) A kind of nutrition type beverage and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150422